Wells Fargo & Company assumed coverage on shares of Metsera (NASDAQ:MTSR – Get Free Report) in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $65.00 price target on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 119.59% from the company’s current price.
MTSR has been the subject of several other research reports. Cantor Fitzgerald initiated coverage on Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating for the company. Evercore ISI initiated coverage on Metsera in a report on Tuesday, February 25th. They issued an “outperform” rating for the company. Bank of America initiated coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective for the company. Finally, Guggenheim increased their price objective on Metsera from $56.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, June 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $55.00.
Metsera Stock Performance
Metsera (NASDAQ:MTSR – Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Strs Ohio bought a new position in Metsera during the 1st quarter valued at approximately $76,000. New York State Common Retirement Fund bought a new position in Metsera during the 1st quarter valued at approximately $131,000. Corebridge Financial Inc. bought a new position in Metsera during the 1st quarter valued at approximately $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Metsera during the 1st quarter valued at approximately $248,000. Finally, MetLife Investment Management LLC bought a new position in Metsera during the 1st quarter valued at approximately $254,000.
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
- Five stocks we like better than Metsera
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- GE Aerospace Turns Engines Into Long-Term Profits
- Market Cap Calculator: How to Calculate Market Cap
- Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes
- Are Penny Stocks a Good Fit for Your Portfolio?
- Marvell’s New AI Chip Deals Capture Wall Street’s Attention
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.